Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jill Wu
CI
Jill Wu
Wall Street Analyst
★★★☆☆
#1611
on 13Foresight · ranked by our own returns
33%
Success Rate
-0.3%
Average Return
1 of 3 calls profitable · +22.9% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 33% of Jill Wu's ratings turned a profit when each position was held for 1 year — averaging -0.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

56 Buy 0 Hold 0 Sell
Jill's Stock Coverage 37 ratings · 2026-07-10
Company Date Position Consensus Price Target 1-Yr Return
HK:2637
Fujian Haixi Pharmaceuticals Co., Ltd. Class H
Jun 10, 2026 BUY Strong Buy
+41.7% avg upside
1 analyst
$280.00
41.71% Upside
·
HK:1093
CSPC Pharmaceutical Group
May 28, 2026 BUY Buy
+42.8% avg upside
6 analysts
$13.05
66.44% Upside
·
HK:1530
3SBio
May 26, 2026 BUY Strong Buy
+68.7% avg upside
5 analysts
$34.87
105.10% Upside
·
ONC
BeOne Medicines
May 07, 2026 BUY Strong Buy
+15.7% avg upside
28 analysts
$392.43
29.59% Upside
-4.8%
TMO
Thermo Fisher
Apr 27, 2026 BUY Strong Buy
+12.7% avg upside
38 analysts
$620.00
18.22% Upside
+12.7%
HK:9969
InnoCare Pharma Ltd.
Apr 24, 2026 BUY Strong Buy
+42.8% avg upside
3 analysts
$18.31
36.45% Upside
·
HK:3692
Hansoh Pharmaceutical Group Company Limited
Apr 02, 2026 BUY Strong Buy
+24.9% avg upside
5 analysts
$46.41
48.87% Upside
·
HK:6699
Angelalign Technology Inc.
Mar 31, 2026 BUY Strong Buy
+15.2% avg upside
2 analysts
$91.89
28.60% Upside
·
HK:1801
Innovent Biologics
Mar 30, 2026 BUY Buy
+15.6% avg upside
7 analysts
$113.86
31.77% Upside
·
HK:2506
Xunfei Healthcare Technology Co., Ltd.
Mar 30, 2026 BUY Strong Buy
+29.4% avg upside
1 analyst
$92.55
29.36% Upside
·
HK:9926
Akeso, Inc.
Mar 30, 2026 BUY Buy
+81.9% avg upside
3 analysts
$185.80
96.37% Upside
·
HK:1177
Sino Biopharmaceutical
Mar 30, 2026 BUY Buy
+58.4% avg upside
6 analysts
$8.70
74.06% Upside
·
HK:9606
Duality Biotherapeutics, Inc.
Mar 29, 2026 BUY Strong Buy
+102.2% avg upside
2 analysts
$383.47
87.80% Upside
·
HK:2269
Wuxi Biologics (Cayman)
Mar 26, 2026 BUY Hold
+2.4% avg upside
4 analysts
$39.00
5.30% Upside
·
HK:2268
WuXi XDC Cayman, Inc.
Mar 25, 2026 BUY Strong Buy
+23.4% avg upside
2 analysts
$82.00
38.10% Upside
·
HK:6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Mar 25, 2026 BUY Strong Buy
+4.2% avg upside
3 analysts
$507.11
6.77% Upside
·
HK:2696
Shanghai Henlius Biotech, Inc. Class H
Mar 24, 2026 BUY Strong Buy
+60.7% avg upside
2 analysts
$99.78
63.12% Upside
·
HK:2367
Giant Biogene Holding Co. Ltd.
Mar 23, 2026 BUY Strong Buy
+124.6% avg upside
3 analysts
$38.70
53.68% Upside
·
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
Mar 12, 2026 BUY Strong Buy
+100.8% avg upside
2 analysts
$10.34
109.38% Upside
·
PFE
Pfizer
Feb 05, 2026 BUY Strong Buy
+38.9% avg upside
45 analysts
$35.46
46.17% Upside
-8.7%
HK:9887
Nanjing Leads Biolabs Co., Ltd. Class H
Sep 03, 2025 BUY Strong Buy
+65.8% avg upside
1 analyst
$80.27
65.85% Upside
·
HK:0013
HUTCHMED (China)
Aug 11, 2025 BUY Buy
+562.6% avg upside
6 analysts
$31.39
79.85% Upside
·
HK:2228
QuantumPharm, Inc.
Apr 03, 2025 BUY Strong Buy
-5.3% avg upside
2 analysts
$7.57
3.16% Downside
·
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
Mar 20, 2025 BUY Strong Buy
+9.5% avg upside
1 analyst
$33.68
9.48% Upside
·
HK:2522
Jiangxi Rimag Group Co., Ltd. Class H
Feb 27, 2025 BUY Strong Buy
+903.6% avg upside
1 analyst
$52.39
903.62% Upside
·
HK:9995
RemeGen Co. Ltd. Class H
Oct 31, 2024 BUY Buy
-36.3% avg upside
2 analysts
$21.09
74.17% Downside
·
HK:1951
Jinxin Fertility Group Ltd.
Sep 02, 2024 BUY Strong Buy
+64.1% avg upside
2 analysts
$3.33
63.24% Upside
·
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
Sep 02, 2024 BUY Strong Buy
-49.4% avg upside
2 analysts
$8.57
53.07% Downside
·
HK:1789
AK Medical Holdings Ltd.
Aug 30, 2024 BUY Strong Buy
+31.9% avg upside
2 analysts
$5.27
0.35% Downside
·
HK:9886
Dingdang Health Technology Group Ltd.
Jun 04, 2024 BUY Strong Buy
+70.0% avg upside
1 analyst
$1.65
70.02% Upside
·
HK:2325
Yunkang Group Limited
Apr 09, 2024 BUY Strong Buy
+1988.0% avg upside
1 analyst
$13.78
1987.95% Upside
·
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Aug 29, 2023 BUY Strong Buy
-52.3% avg upside
1 analyst
$22.36
52.34% Downside
·
HK:1833
Ping An Healthcare and Technology Company
Aug 28, 2023 BUY Buy
+222.5% avg upside
3 analysts
$23.80
222.46% Upside
·
HK:9885
YSB Inc.
Aug 25, 2023 BUY Strong Buy
+1349.3% avg upside
1 analyst
$57.97
1349.26% Upside
·
HK:2096
Simcere Pharmaceutical Group Limited
Aug 23, 2023 BUY Strong Buy
-31.4% avg upside
1 analyst
$8.15
31.45% Downside
·
NBP
NovaBridge Biosciences
Aug 03, 2023 HOLD Strong Buy
+1034.1% avg upside
14 analysts
·
HK:2487
Cutia Therapeutics
Jul 24, 2023 BUY Strong Buy
+1134.5% avg upside
1 analyst
$33.21
1134.51% Upside
·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Jill Wu — Frequently Asked Questions
How accurate are Jill Wu's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Jill's ratings were profitable over a one-year hold, with an average return of -1.0% per rating, or +16.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jill ranked on 13Foresight?
Jill Wu is currently ranked #1611 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jill cover?
Jill most recently has ratings on HK:2637, HK:1093, HK:1530, ONC, TMO, HK:9969, HK:3692, HK:6699, HK:1801, HK:2506, HK:9926, HK:1177 and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.